GLP-1 agonists are medications that mimic gut hormones to regulate blood sugar and appetite. They are prescribed primarily for adults with type 2 diabetes or obesity when lifestyle measures alone have not achieved target outcomes. Candidates typically have a BMI of 30 or higher, or a BMI of 27 with weight-related conditions such as hypertension or dyslipidemia. A confirmed diagnosis of type 2 diabetes with inadequate control on metformin or other oral agents also supports use. Individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are generally excluded. Pregnancy, severe gastrointestinal disease, and certain pancreatitis histories further limit eligibility. A clinician evaluates these factors through history, labs, and physical examination before any prescription.
Who Should Start a GLP-1 Agonist
Eligibility centers on clinical need rather than age or weight alone. Adults with type 2 diabetes whose A1C remains above target despite optimized oral therapy often qualify. People living with obesity who have not reached sustained weight loss through diet and exercise may also meet criteria when cardiovascular risk factors are present. The decision requires documented failure of first-line interventions and absence of contraindications. Shared decision-making incorporates patient goals, tolerance for weekly injections, and commitment to follow-up monitoring.
How to Start GLP-1 Agonist Therapy
Initiation follows a structured medical pathway. First obtain a full evaluation including renal function, thyroid labs, and medication review. Next receive education on proper injection technique and expected gastrointestinal side effects. Dosing begins at the lowest level and increases gradually over weeks to improve tolerability. Regular follow-up visits track weight, A1C, and any adverse reactions. Dose adjustments or discontinuation occur based on response and safety signals.
Why It Matters
Starting the correct therapy at the right time improves glycemic control and reduces cardiovascular events in appropriate patients. Early identification prevents prolonged hyperglycemia and its complications. Structured initiation lowers discontinuation rates caused by unmanaged side effects. Clear criteria protect individuals for whom these agents are unsafe.
Practical Steps to Begin Treatment
- Schedule an appointment with an endocrinologist or primary-care provider experienced in metabolic care.
- Complete required labs and share full medical history including prior weight-loss attempts.
- Discuss administration schedule, storage needs, and plans for dose titration.
- Arrange follow-up within four to six weeks to assess tolerance and adjust dose.
- Establish ongoing monitoring for nutritional intake, muscle preservation, and any new symptoms.
Eligibility Criteria Overview
| Factor | Typical Threshold or Consideration | Notes |
|---|---|---|
| BMI | ≥30 or ≥27 with comorbidities | Measured in clinic |
| Diabetes status | A1C above target on first-line agents | Confirmed diagnosis required |
| Contraindications | Personal/family medullary thyroid cancer history | Absolute exclusion |
| Pregnancy | Current or planned within two months of stopping | Requires alternative management |
| GI history | Severe gastroparesis or pancreatitis | Case-by-case review |
FAQ
What medical conditions most commonly lead to a GLP-1 agonist prescription?
Type 2 diabetes with persistent hyperglycemia and obesity with related cardiometabolic risk factors are the primary indications. Clinicians confirm these through labs and history before prescribing.
How is the first dose of a GLP-1 agonist administered and monitored?
The initial dose is given under guidance with training on subcutaneous injection sites. Patients track symptoms daily for the first week, then return for labs and dose review within a month.
Can someone with a history of pancreatitis still qualify?
Prior pancreatitis usually prompts caution or exclusion. The prescriber weighs individual risk against potential benefit using imaging and enzyme history.
Last updated: October 12, 2026